News & Updates

PF-06700841 shows therapeutic potential in moderate-to-severe plaque psoriasis

14 May 2020

The oral TYK2/JAK1 inhibitor PF-06700841 appears to be effective in the treatment of patients with moderate-to-severe plaque psoriasis, with a tolerable safety profile, according to the results of a phase IIa study.

PF-06700841 shows therapeutic potential in moderate-to-severe plaque psoriasis

14 May 2020

Baricitinib benefits even AD patients with comorbidities

08 May 2020 by

Treatment with baricitinib led to clinically meaningful improvements in itch and skin symptoms in patients with moderate-to-severe atopic dermatitis (AD), even in those with additional comorbid atopic conditions, according to a pooled analysis of two phase III studies released in the AAAAI 2020 Meeting.

Baricitinib benefits even AD patients with comorbidities

08 May 2020

Proteins in blood could predict psoriasis response to tofacitinib, etanercept

06 May 2020

Predictive models that include blood inflammatory proteins such as interleukins (IL) 17A and 17C may help gauge the clinical response of psoriasis patients to tofacitinib and etanercept, a new study has shown.

Proteins in blood could predict psoriasis response to tofacitinib, etanercept

06 May 2020

Alopecia areata bidirectionally linked to major depressive disorder

21 Apr 2020

A bidirectional association exists between alopecia areata (AA) and major depressive disorder (MDD) among probands and unaffected siblings, reveals a study. This suggests that shared familial mechanisms tend to cause AA and MDD.

Alopecia areata bidirectionally linked to major depressive disorder

21 Apr 2020

Photodynamic therapy plus aminolevulinic acid may improve cutaneous SCCis

20 Apr 2020

Treatment with photodynamic therapy (PDT) plus aminolevulinic acid (ALA) appears to be effective for some cases of cutaneous squamous cell carcinoma in situ (SCCis), suggests a recent study. In addition, anatomic location, tumour diameter and ALA incubation time contribute to the effectiveness of the combined therapy.

Photodynamic therapy plus aminolevulinic acid may improve cutaneous SCCis

20 Apr 2020

Predictors of higher sun exposure, poorer sun protection identified

17 Apr 2020 by

Men and young adults may have greater sun exposure, but are also less likely to use sun protection, according to a study from Singapore.

Predictors of higher sun exposure, poorer sun protection identified

17 Apr 2020

Nanomaterial shows potential for AD treatment

17 Apr 2020 by

A customized nanotextile garment for wet wrap therapy (WWT) for moderate-to-severe atopic dermatitis (AD) was as effective as viscose yet superior in terms of patient acceptability, a Singapore study has shown.

Nanomaterial shows potential for AD treatment

17 Apr 2020

Delgocitinib ointment safe, effective for moderate/severe atopic dermatitis

01 Apr 2020 by

Treatment with delgocitinib 0.5% ointment leads to clinical improvements in adult patients with moderate-to-severe atopic dermatitis (AD) for up to 28 weeks, according to a Japan study.

Delgocitinib ointment safe, effective for moderate/severe atopic dermatitis

01 Apr 2020

Lanadelumab may prevent hereditary angioedema attacks

31 Mar 2020 by

Interim findings from the HELP/HELP OLE* studies presented at AAAAI 2020 have shown that the monoclonal antibody lanadelumab has the potential to reduce hereditary angioedema (HAE) attack rates.

Lanadelumab may prevent hereditary angioedema attacks

31 Mar 2020

Maternal terbinafine use does not affect foetal, pregnancy outcomes

27 Mar 2020 by

Exposure to oral or topical terbinafine during pregnancy does not increase the risk of major malformations and spontaneous abortion, according to a recent study.

Maternal terbinafine use does not affect foetal, pregnancy outcomes

27 Mar 2020

News & Updates

Filter by Specialty:

Specialty:

PF-06700841 shows therapeutic potential in moderate-to-severe plaque psoriasis

PF-06700841 shows therapeutic potential in moderate-to-severe plaque psoriasis

Baricitinib benefits even AD patients with comorbidities

Baricitinib benefits even AD patients with comorbidities

Proteins in blood could predict psoriasis response to tofacitinib, etanercept

Proteins in blood could predict psoriasis response to tofacitinib, etanercept

Alopecia areata bidirectionally linked to major depressive disorder

Alopecia areata bidirectionally linked to major depressive disorder

Photodynamic therapy plus aminolevulinic acid may improve cutaneous SCCis

Photodynamic therapy plus aminolevulinic acid may improve cutaneous SCCis

Predictors of higher sun exposure, poorer sun protection identified

Predictors of higher sun exposure, poorer sun protection identified

Nanomaterial shows potential for AD treatment

Nanomaterial shows potential for AD treatment

Delgocitinib ointment safe, effective for moderate/severe atopic dermatitis

Delgocitinib ointment safe, effective for moderate/severe atopic dermatitis

Lanadelumab may prevent hereditary angioedema attacks

Lanadelumab may prevent hereditary angioedema attacks

Maternal terbinafine use does not affect foetal, pregnancy outcomes

Maternal terbinafine use does not affect foetal, pregnancy outcomes